Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 Nov 2;313(7065):1127–1130. doi: 10.1136/bmj.313.7065.1127

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

J P Vandenbroucke 1, F J van der Meer 1, F M Helmerhorst 1, F R Rosendaal 1
PMCID: PMC2352463  PMID: 8916702

Abstract

The factor V Leiden mutation is the most common genetic risk factor for deep vein thrombosis: it is present in about 5% of the white population. The risk of deep vein thrombosis among women who use oral contraceptives is greatly increased by the presence of the mutation. The same seems to be true of the risk of postpartum thrombosis. Several authors have called for all women to be screened before prescription of oral contraceptives and during pregnancy. Such a policy might deny effective contraception to a substantial number of women while preventing only a small number of deaths due to pulmonary emboli. Moreover, in pregnancy the ensuing use of oral anticoagulation prophylaxis might carry a penalty of fatal bleeding that is equal to or exceeds the risk of death due to postpartum thrombosis. It might pay, however, to take a personal and family history of deep vein thrombosis when prescribing oral contraceptives or at a first antenatal visit to detect women from families with a tendency to multiple thrombosis.

Full text

PDF
1127

Images in this article

1129p1129-a
on p.1129

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson F. A., Jr, Wheeler H. B., Goldberg R. J., Hosmer D. W., Patwardhan N. A., Jovanovic B., Forcier A., Dalen J. E. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933–938. [PubMed] [Google Scholar]
  2. Badaracco M. A., Vessey M. P. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J. 1974 Feb 9;1(5901):215–217. doi: 10.1136/bmj.1.5901.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  4. Bloemenkamp K. W., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 Dec 16;346(8990):1593–1596. doi: 10.1016/s0140-6736(95)91929-5. [DOI] [PubMed] [Google Scholar]
  5. Briët E., van der Meer F. J., Rosendaal F. R., Houwing-Duistermaat J. J., van Houwelingen H. C. The family history and inherited thrombophilia. Br J Haematol. 1994 Jun;87(2):348–352. doi: 10.1111/j.1365-2141.1994.tb04920.x. [DOI] [PubMed] [Google Scholar]
  6. Carter C. J. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 1994 May-Jun;36(6):423–438. doi: 10.1016/s0033-0620(94)80051-0. [DOI] [PubMed] [Google Scholar]
  7. Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med. 1995 Mar;237(3):221–227. doi: 10.1111/j.1365-2796.1995.tb01170.x. [DOI] [PubMed] [Google Scholar]
  8. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994 Sep;94(3):923–927. doi: 10.1172/JCI117458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahlbäck B. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost. 1995 May;73(5):739–742. [PubMed] [Google Scholar]
  10. Fihn S. D. Aiming for safe anticoagulation. N Engl J Med. 1995 Jul 6;333(1):54–55. doi: 10.1056/NEJM199507063330112. [DOI] [PubMed] [Google Scholar]
  11. Hellgren M., Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995 Jul;173(1):210–213. doi: 10.1016/0002-9378(95)90192-2. [DOI] [PubMed] [Google Scholar]
  12. Imperiale T. F., Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994 Jun 8;271(22):1780–1785. [PubMed] [Google Scholar]
  13. Jick H., Jick S. S., Gurewich V., Myers M. W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16;346(8990):1589–1593. doi: 10.1016/s0140-6736(95)91928-7. [DOI] [PubMed] [Google Scholar]
  14. Koster T., Small R. A., Rosendaal F. R., Helmerhorst F. M. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med. 1995 Jul;238(1):31–37. doi: 10.1111/j.1365-2796.1995.tb00896.x. [DOI] [PubMed] [Google Scholar]
  15. Majerus P. W. Human genetics. Bad blood by mutation. Nature. 1994 May 5;369(6475):14–15. doi: 10.1038/369014a0. [DOI] [PubMed] [Google Scholar]
  16. Pabinger I., Kyrle P. A., Heistinger M., Eichinger S., Wittmann E., Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994 Apr;71(4):441–445. [PubMed] [Google Scholar]
  17. Pasi K. J., Perry D. J., Lee C. A. Thromboembolism and the combined oral contraceptive pill. Lancet. 1995 Jun 3;345(8962):1437–1437. doi: 10.1016/s0140-6736(95)92625-9. [DOI] [PubMed] [Google Scholar]
  18. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  19. Ridker P. M., Miletich J. P., Stampfer M. J., Goldhaber S. Z., Lindpaintner K., Hennekens C. H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995 Nov 15;92(10):2800–2802. doi: 10.1161/01.cir.92.10.2800. [DOI] [PubMed] [Google Scholar]
  20. Rosendaal F. R., Koster T., Vandenbroucke J. P., Reitsma P. H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995 Mar 15;85(6):1504–1508. [PubMed] [Google Scholar]
  21. Rosendaal F. R. Oral contraceptives and screening for factor V Leiden. Thromb Haemost. 1996 Mar;75(3):524–525. [PubMed] [Google Scholar]
  22. Sachs B. P., Brown D. A., Driscoll S. G., Schulman E., Acker D., Ransil B. J., Jewett J. F. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med. 1987 Mar 12;316(11):667–672. doi: 10.1056/NEJM198703123161105. [DOI] [PubMed] [Google Scholar]
  23. Toglia M. R., Weg J. G. Venous thromboembolism during pregnancy. N Engl J Med. 1996 Jul 11;335(2):108–114. doi: 10.1056/NEJM199607113350207. [DOI] [PubMed] [Google Scholar]
  24. Treffers P. E., Huidekoper B. L., Weenink G. H., Kloosterman G. J. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet. 1983 Aug;21(4):327–331. doi: 10.1016/0020-7292(83)90024-3. [DOI] [PubMed] [Google Scholar]
  25. van der Meer F. J., Rosendaal F. R., Vandenbroucke J. P., Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993 Jul 12;153(13):1557–1562. doi: 10.1001/archinte.153.13.1557. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES